Galmed rises on expansion of development strategy for lead candidate
17/05/2022 13:07
** Isreli drug developer Galmed Pharmaceuticals' shares
GLMD.O rise 7.6% to $0.62 premarket
** Co expands clinical development strategy into new
anti-fibrotic indications to maximize potential of its lead
compound, aramchol, while also discontinuing the open label part
of a study on the drug urn:newsml:reuters.com:*:nPnbj6NZBa
** 4 of 5 brokerages rate the stock "buy" or higher, 1
"hold"; their median PT is $5
** Stock down 68% YTD, up to last close
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))